Prostate cancer stands as the most common cancer in men, and research into its genesis and spread is still vital. The idea that the human genome's transcriptional activity is more widespread than previously thought has received empirical validation through the application of deep sequencing-based transcriptome profiling techniques. An assortment of noncoding transcripts longer than 200 nucleotides is referred to as long noncoding RNAs (lncRNAs). Transposable elements comprise a substantial portion of the human genome, with projections indicating that their prospective proportion may reach 90%. Considering they can interact directly with proteins, alter the transcriptional activity of coding genes, and perhaps encode proteins, lncRNAs possess the capability to regulate a variety of biological processes. LncRNAs have been recognized to be key factors in the development of several types of human cancers, including lung, colorectal, and breast cancers, alongside other pathological processes that have a significant impact on the diagnosis and survival of cancer individuals. Furthermore, lncRNAs' discernible expression patterns throughout various cancer scenarios significantly raise their potential as biomarkers and therapeutic targets. We conducted an extensive analysis of the prevailing academic literature on the interaction between lncRNAs and prostate cancer in order to present a solid foundation for potential future studies on the prevention and intervention of prostate cancer. The discourse additionally expands on lncRNAs' prospective applications as targets and biomarkers for medical therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clgc.2024.102213 | DOI Listing |
Cell Biochem Biophys
December 2024
Biology Department, Université de Moncton, Moncton, NB, Canada.
Targeting more than one in nine men before age 70, prostate cancer is the most common type of cancer in men. The increased levels of cyclins, leading to activation of cyclin-dependent kinases (CDKs), play a critical role in the increased proliferation of prostate cancer cells. In this study, the regulation of the cyclin D1 (CCND1) promoter activity by activator protein-1 (AP-1) and SRY-related HMG-box (SOX) transcription factors has been characterized in PC3 prostate cancer cells.
View Article and Find Full Text PDFJ Xenobiot
December 2024
Infectious and Immune Diseases Division, CHU de Québec-Université Laval Research Center, Quebec, QC G1V 4G2, Canada.
Over the last decades, the human species has seen an increase in the incidence of pathologies linked to the genitourinary tract. Observations in animals have allowed us to link these increases, at least in part, to changes in the environment and, in particular, to an increasing presence of endocrine disruptors. These can be physical agents, such as light or heat; natural products, such as phytoestrogens; or chemicals produced by humans.
View Article and Find Full Text PDFJ Funct Biomater
December 2024
Division of Immunology and Microbiology, Iv. Javakhishvili Tbilisi State University, 1, Ilia Tchavchavadze Ave., 0179 Tbilisi, Georgia.
The rapid progress in nanotechnology has introduced multifunctional iron oxide nanoparticles as promising agents in cancer treatment. This research focused on the synthesis and assessment of citric-acid-coated, folic-acid-conjugated nanoparticles loaded with doxorubicin, evaluating their therapeutic potential in tumor models. An advanced automated continuous technology line (CTL) utilizing a controlled co-precipitation method was employed to produce highly dispersive, multifunctional nanofluids with a narrow size distribution.
View Article and Find Full Text PDFJ Pers Med
December 2024
Department of Urology, Changbing Show Chwan Memorial Hospital, Changhua 505, Taiwan.
Prostate cancer (PCa) outcomes vary significantly across risk groups. In early-stage localized PCa, the functional outcomes following radical prostatectomy (RP) can be severe, prompting increased interest in focal therapy, particularly High-Intensity Focused Ultrasound (HIFU). This study is to summarize the current clinical trials of HIFU on PCa.
View Article and Find Full Text PDFJ Pers Med
December 2024
Centre Hospitalier Universitaire de Bordeaux, Service de Radiologie et Imagerie Médicale de l'adulte, Place Amélie Raba Léon, 33076 Bordeaux, France.
MRI-guided focal laser ablation (MRI-FLA) is an emerging minimally invasive technique for treating localized prostate tumors, aiming to provide effective cancer control while minimizing side effects. This meta-analysis systematically evaluates the clinical outcomes, technical efficacy, and complication rates associated with MRI-FLA to better understand its therapeutic potential and safety profile in prostate cancer management. In July 2024, PubMed (MEDLINE) was searched for eligible trials using the PRISMA guidelines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!